Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”), a leader in developing technology to create psychedelic-related treatments, is pleased to announce the addition of Rob Hill to the Board of Directors. Mr. Hill brings over twenty years of senior leadership experience in capital markets, and specific domain expertise in heavily regulated markets experiencing hyper-growth, big data and compliance management. He has extensive management and board-level experience applying his deep operational and financial knowledge to strategic leadership, technology innovation, financing and mergers and acquisitions. Mr. Hill will replace Terese Gieselman on the Board.
Mind Cure is investing significant resources into its proprietary platforms, and this transition at the director level further enhances the Company’s leadership in these key technology areas. Mind Cure has positioned itself as a technology leader in the psychedelics industry with its recently-announced proprietary iSTRYM and PsyCollage platforms, and continues to build the team needed to execute successfully on its robust technology strategy.
“Firstly, I would like to thank Ms. Gieselman for her help in guiding Mind Cure to where it is today, particularly with her financial and capital markets expertise,” said Kelsey Ramsden, President & CEO. “We are thrilled to welcome Mr. Hill to our Board of Directors. We strongly believe in the therapeutic importance and commercial potential of technology with regards to psychedelic drugs, treatments and therapies, and continue to build a world-class technology leadership group. Mr. Hill’s track record of success in the capital markets and specific technology management expertise will add immense value to Mind Cure.”
As part of its mission to identify, develop and commercialize products that enhance mental health and wellness, ease suffering and increasing productivity, Mind Cure is investing significantly in digital therapeutics technology. There is a particular focus on capturing, managing and enhancing data through the application of AI and machine learning, both with iSTRYM and PsyCollage.
Mr. Hill’s extensive expertise in mergers and acquisitions will bring significant value to the Company as it pursues its aggressive growth plan, both organically and by acquisition.
“Throughout my career, I have worked extensively to embrace and adopt innovative technology and know the importance of employing analytics to extract meaningful insights,” said Mr. Hill. “I look forward to helping Mind Cure’s leadership team further establish the company as a technology leader in psychedelics, and advising on the strategic direction and M&A opportunities of the Company.”